Market Report Segmentation:
- By Therapeutic Area
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Metabolic Disorders
- Neurological Disorders
- Autoimmune Diseases
- Others (Respiratory Diseases, Musculoskeletal Disorders, etc.)
- By Drug Type
- Small Molecule Synthetic Drugs
- Small Molecule Biologics
- Small Molecule Vaccines
- Small Molecule Gene Therapies
- Others (Peptides, Oligonucleotides, etc.)
- By Target Class
- G-protein-coupled Receptors (GPCRs)
- Kinases
- Proteases
- Ion Channels
- Nuclear Receptors
- Enzymes
- Others (DNA/RNA, Cytokines, etc.)
- By Molecule Type
- Synthetic Compounds
- Natural Compounds
- Peptides
- Oligonucleotides
- Others (Carbohydrates, Lipids, etc.)
- By Phase of Development
- Preclinical
- Phase I
- Phase II
- Phase III
- Approved/Marketed Drugs
- By Service Type
- Lead Identification Services
- Lead Optimization Services
- Candidate Selection Services
- Bioavailability and Solubility Studies
- Others (Pharmacokinetic Studies, Toxicology Studies, etc.)
- By Technology
- High-throughput Screening (HTS)
- Computer-aided Drug Design (CADD)
- Combinatorial Chemistry
- Bioinformatics
- Structural Biology
- Nanotechnology
- Others (Genomics, Proteomics, etc.)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Small Molecule Drug Discovery industry is estimated to be USD 35.2 billion in 2023.
Increasing prevalence of chronic diseases, Rising demand for personalized medicine, Advancements in computational drug discovery techniques, Growing pharmaceutical R&D investments, Increasing healthcare expenditure, Aging population, Sedentary lifestyles and rising obesity rates, Improved diagnostic techniques, Increased disease awareness, Development of targeted therapies
High costs of drug development, Stringent regulatory requirements for approval, Patent expiration of blockbuster drugs, Lack of skilled professionals, Pricing pressures and reimbursement challenges, Lengthy development and approval timelines, Ethical concerns and public perception
The leading component segment in the Small Molecule Drug Discovery Market is the small molecule synthetic drugs segment, which includes chemically synthesized organic compounds used for various therapeutic areas.
The major players operating in the Small Molecule Drug Discovery Market include Pfizer Inc., Novartis AG, Merck & Co., Inc., Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Sanofi, Bristol-Myers Squibb Company, and Eli Lilly and Company.
The Small Molecule Drug Discovery Market is expected to grow at a CAGR of 8.6% from 2024 to 2031, and is projected to reach a market size of USD 68.1 billion by 2031.
Increasing prevalence of chronic diseases, Rising demand for personalized medicine, Advancements in computational drug discovery techniques, Growing pharmaceutical R&D investments, Increasing healthcare expenditure, Aging population, Sedentary lifestyles and rising obesity rates, Improved diagnostic techniques